Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective vigilantly but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last few shares of mine. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out what follows prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a very promotional image in the Uptick Newswire job interview that I came away with an inadequate opinion of the business.

Irony of irony, my poor opinion of the business has grown steadily, although the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the technology and connected intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) and the first brand new drug program endorsement ($five million), and even royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and many indications, it has this single treatments in addition to a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic company with diverse interests albeit centered on leronlimab, multiple illness sorts, multiple delivering presentations and multiple publications.

Might all of it be smoke and mirrors? That’s a question I have been asking myself through the very beginning of my interest in this particular organization. Judging by way of the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a classic battleground, or some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *